Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2029

1.1 List of Tables
1.2 List of Figures

2.1 Global ALS Market Expected to Grow to $1.04B in 2029
2.2 Biogen, Mitsubishi, and BrainStorm Are Forecast to Lead the ALS Market By 2029
2.3 Unmet Need Will Remain for the Identification of Curative Drugs and Biomarkers
2.4 ALS Pipeline Moving Toward Disease-Modifying Drugs That Will Likely Transform Treatment Algorithm Especially for FALS Type
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.3.1 Complications
4.4 Quality of Life

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for ALS (2019-2029)
5.5.1 Total Prevalent Cases of ALS
5.5.2 Sex-Specific Total Prevalent Cases of ALS
5.5.3 Age-Specific Total Prevalent Cases of ALS
5.5.4 Total Prevalent Cases of ALS by Type
5.5.5 Diagnosed Prevalent Cases of ALS
5.5.6 Sex-Specific Diagnosed Prevalent Cases of ALS
5.5.7 Age-Specific Diagnosed Prevalent Cases of ALS
5.5.8 Diagnosed Prevalent Cases of ALS by Type
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6.1 Overview

7.1 Overview
7.2 Curative Drugs
7.3 Earlier Diagnosis
7.4 Identification of Biomarkers Associated with ALS
7.5 Extended Patient Survival and Improved Control of Symptoms

8.1 Overview
8.1.1 Novel Targets
8.1.2 Disease-Modifying Biologic Therapies
8.1.3 Reformulations
8.2 Clinical Trials Design
8.2.1 Clinically Meaningful Endpoints
8.2.2 Clinical Trial Duration
8.2.3 Patient Recruitment

9.1 Overview
9.2 Innovative Early-Stage Approaches

10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 Canada
11 Appendix

Table 1: ALS: Key Metrics in the 8MM
Table 2: Genes Involved in the Familial Forms of ALS
Table 3: Symptoms of ALS
Table 4: Risk Factors and Comorbidities for ALS
Table 5: Leading Treatments for ALS, 2020
Table 6: Treatment Guidelines for ALS
Table 7: Comparison of Therapeutic Classes in Development for ALS, 2019-2029
Table 8: Innovative Early-Stage Approaches for ALS, 2020
Table 9: Clinical Benchmark of Key Pipeline Drugs - ALS
Table 10: Commercial Benchmark of Key Pipeline Drugs - ALS
Table 11: Commercial Benchmark of Key Pipeline Drugs - ALS
Table 12: Key Events Impacting Sales for ALS, 2019-2029
Table 13: ALS Market - Global Drivers and Barriers, 2019-2029
Table 14: Key Historical and Projected Launch Dates for ALS
Table 15: Key Historical and Projected Patent Expiry Dates for ALS
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for ALS in 2019 and 2029
Figure 2: Competitive Assessment of Marketed and Pipeline Drugs, Benchmarked Against the SOC, Rilutek
Figure 3: Pathophysiology of ALS
Figure 4: Staging Systems for ALS
Figure 5: 8MM, Total Prevalence of ALS (%), Both Sexes, Ages =40 Years, 2019
Figure 6: 8MM, Diagnosed Prevalence of ALS, Both Sexes, Ages =40 Years, 2019
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of ALS
Figure 8: 8MM, Sources Used to Forecast the Total and Diagnosed Prevalent Cases of ALS by Type
Figure 9: 8MM, Total Prevalent Cases of ALS, N, Both Sexes, Ages =40 Years, 2019
Figure 10: 8MM, Total Prevalent Cases of ALS, N, by Sex, Ages =40 Years, 2019
Figure 11: 8MM, Total Prevalent Cases of ALS by Age, N, Both Sexes, 2019
Figure 12: 8MM, Total Prevalent Cases of ALS by Type, N, Both Sexes, Ages =40 Years, 2019
Figure 13: 8MM, Diagnosed Prevalent Cases of ALS, N, Both Sexes, Ages =40 Years, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of ALS, N, by Sex, Ages =40 Years, 2019
Figure 15: 8MM, Diagnosed Prevalent Cases of ALS by Age, N, Both Sexes, 2019
Figure 16: 8MM, Diagnosed Prevalent Cases of ALS by Type, N, Both Sexes, Ages =40 Years, 2019
Figure 17: Unmet Needs and Opportunities in ALS
Figure 18: Overview of the Development Pipeline in ALS
Figure 19: Key Phase IIb and III Trials for Promising Pipeline Agents in ALS
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Rilutek
Figure 21: Global (8MM) Sales Forecast by Country for ALS in 2019 and 2029
Figure 22: Sales Forecast by Class for ALS in the US in 2019 and 2029
Figure 23: Sales Forecast by Class for ALS in the 5EU in 2019 and 2029
Figure 24: Sales Forecast by Class for ALS in Japan in 2019 and 2029
Figure 25: Sales Forecast by Class for ALS in Canada in 2019 and 2029